HER2+ Breast Cancer | Specialty

De-escalated, Chemo-Free Neoadjuvant Path Viable in HER2+/HR+ Breast Cancer

July 3rd 2018

A de-escalated, chemotherapy-free neoadjuvant regimen of letrozole plus dual HER2 blockade showed promise in patients with HER2+/HR+ breast cancer who first achieved a molecular response to 2 weeks of letrozole.

Neratinib Approaches EU Approval for HER2+ Breast Cancer

June 29th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of neratinib for the extended adjuvant treatment of adult patients with early stage hormone receptor–positive, HER2-overexpressed/amplified breast cancer following postoperative trastuzumab.

Dr. Mitri on the Treatment Landscape of HER2+ Breast Cancer

June 29th 2018

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the treatment landscape of HER2-positive breast cancer.

Dr. McCann on Ongoing Research in HER2-Positive Breast Cancer

June 27th 2018

Kelly McCann, MD, PhD, a medical oncologist in the Breast Cancer Research Group at the University of California, Los Angeles, discusses ongoing research in the field of HER2-positive breast cancer.

Dr. Esteva Discusses Adjuvant Trastuzumab in HER2+ Breast Cancer

June 27th 2018

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses adjuvant trastuzumab (Herceptin) in HER2-positive early breast cancer.

Trastuzumab Duocarmazine Active in HER2-Positive Breast Cancer

June 21st 2018

The HER2-targeting antibody-drug conjugate (vic-)trastuzumab duocarmazine (SYD985) showed promising clinical activity in heavily-pretreated women with metastatic breast cancer.

Dr. Ali on the Future of Adjuvant Care for HER2+ Breast Cancer

June 21st 2018

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses the future of adjuvant treatment for patients with HER2-positive breast cancer.

Expert Highlights Nuances in HER2-Positive Breast Cancer Care

June 21st 2018

Zahi Mitri, MD, discusses adjuvant advances and other emerging trends in the treatment of patients with HER2-positive breast cancer.

Neratinib/T-DM1 Combo Shows Promise in HER2-Positive Breast Cancer

June 18th 2018

The combination of neratinib and T-DM1 induced an overall response rate of 60% in previously-treated women with HER2-positive metastatic breast cancer.

Tracing Tucatinib's Role in HER2+ Breast Cancer Treatment

June 15th 2018

Rashmi K. Murthy, MD, discusses the clinical benefit of tucatinib after isolated brain progression in patients with HER2-positive breast cancer.

Trastuzumab Deruxtecan Efficacious in Breast Cancer Across Varying HER2 Levels

June 13th 2018

Long-term findings from a phase I study of trastuzumab deruxtecan showed that the investigational HER2-targeting antibody-drug conjugate had antitumor activity in multiple tumor types that expressed HER2 at varying levels.

Tucatinib Active in Heavily Pretreated HER2+ Breast Cancer

June 13th 2018

Tucatinib used in combination with capecitabine, trastuzumab, or both agents showed promising antitumor activity in heavily pretreated women with HER2-positive breast cancer with or without brain metastases.

Dr. Roussos Torres on the Importance of Preclinical Models in HER2+ Breast Cancer

June 9th 2018

Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the importance of preclinical models in HER2-positive breast cancer.

Dr. Valdes-Albini Discusses Trials in HER2+ Breast Cancer

June 7th 2018

Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses ongoing clinical trials of patients with HER2-positive breast cancer.

Endocrine Therapy Alone Is Sufficient in HR+/HER2- Breast Cancer With Intermediate Recurrence Score

June 3rd 2018

Adjuvant endocrine therapy alone is noninferior to adjuvant chemoendocrine therapy in patients with hormone receptor–positive, HER2-negative, node-negative early-stage breast cancer.

Practice Changes for Use of Immunotherapy in NSCLC: Q&A

June 2nd 2018

Using Immunotherapy Beyond Progression in NSCLC

June 2nd 2018

Optimizing Immunotherapy in the NSCLC Treatment Paradigm

June 2nd 2018

Tumor Mutational Burden in NSCLC: Should it be Routine?

June 2nd 2018

Impact of Data on the Real-Life Treatment of NSCLC

June 2nd 2018